MTD vs. RVMD: Mettler-Toledo vs. Revolution Medicines Stock Comparison

Company Profile

Mettler-Toledo (MTD) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Mettler-Toledo (MTD) has more than two decades of public-market history since November 14, 1997, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Mettler-Toledo (MTD) has no ROE value reported for this period; Revolution Medicines (RVMD) reports a negative figure of -93.56%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

Mettler-Toledo (MTD) at 22.25% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Mettler-Toledo (MTD) reports 28.70%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Mettler-Toledo (MTD) reports revenue growth of 3.98%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

Revolution Medicines (RVMD) at 0.50 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Mettler-Toledo (MTD) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Mettler-Toledo (MTD) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Mettler-Toledo (MTD) at 8.16 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Measured against book value, both Mettler-Toledo (MTD) at 442.71 and Revolution Medicines (RVMD) at 17.31 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics